CClinicalTrials.gg
Status unknownNCT03907306Updated Apr 8, 2019

Cold Argon Plasma (CAP) Application in the Wound Treatment After Open Hemorrhoidectomy

An interventional study of Wound healing in Cold Argon Plasma, sponsored by State Scientific Centre of Coloproctology, Russian Federation. Status unknown at 1 site in Russian Federation. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-08.

Sponsored by State Scientific Centre of Coloproctology, Russian Federation · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2019), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Sep 2018, registered Mar 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This is single-center, prospective, randomized study

Read the detailed description

This study will include patients with 3-4 stage hemorrhoids. They will undergo an operation of open hemorrhoidectomy. Patients will be divided into a study group and a control group. Study group patients during a post-operation period except a standard treatment (antiseptic solutions and antibacterial and wound healing ointments) of a post-operation wound will be treated with cold argon plasma. Control group patients will be treated with a standard treatment. Wound healing speed will be researched.

02

Conditions studied

  • Cold Argon Plasma

Keywords

  • Cold argon plasma
  • hemorrhoidectomy
  • wound healing
  • hemorrhoids
03

In context

Lead sponsor

State Scientific Centre of Coloproctology, Russian Federation is the lead sponsor of 25 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 3-4 stage hemorrhoids
  • 3 hemorrhoids

Exclusion criteria

Exclusion Criteria:

  • patients underwent anal canals intervention
  • acute hemorrhoids
  • inflammatory bowel disease
  • co-morbidity diseases of anal canal and perianal area
  • concurrent conditions in the stage of decompensation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Patients after open hemorrhoidectomy (study group)

    Patients to whom during a post-operation period cold argon plasma and a standard treatment will be treated. Cold argon plasma will be applied during 4 minutes at one session on the 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 14th, 21nd, 30th day after operation. The usage of antibacterial and wound healing ointments daily.

    Procedure: Wound healing

  • Active comparator
    Patients after open hemorrhoidectomy (control group)

    Patients who during a post-operation period will be treated with a standard treatment.The usage of antibacterial and wound healing ointments daily.

    Procedure: Wound healing

Interventions

  • ProcedureWound healing

    The measurement of a wound area is committed on the 2nd, 8th, 14th, 21nd and 30th day after operation. By means of the mathematical formulas the wound healing speed will be defined. The wound process will be researched with the help of cytological method. The wound prints will be taken on the 2nd, 8th, 14th, 21nd and 30th day after operation. Microbiological research of a wound will be held on the 2nd, 8th, 14th, 21nd and 30th day after operation (in study groups before and after the usage of CAP, in control groups once). The pain assessment will be measured by a visual analogue scale on the 2nd, 3rd,4th, 5th, 6th, 7th, 8th, 14th, 21nd and 30th day after operation. The life quality will be researched by means of Health Status Survey on the 8th and 30th day before operation.

06

What researchers measure

Primary outcomes

  1. Wound healing

    Total wound healing will be assessed with the help of cytological and macroscopic methods.In the cytological method the presence of fibroblasts, mature epithelial cells, scar tissue formation and the absence of inflammation will be the criterion of wound healing, as well as the presence of macroscopic features of wound epithelialization.

    Time frame: 30 days

Secondary outcomes

  1. Pain Intensity Measure

    Visual analogue scale (0-10 points)

    Time frame: 2, 3, 4, 5, 6, 7, 8, 14, 21, 30 days

  2. Life quality

    Short Form - 36 Health Status Survey

    Time frame: before operation, 8 days, 30 days

  3. Microbiological contamination of wound area

    Microbiological contamination from the post operation wound area. The assessment of CAP effect on bacteria in planktonic and biofilm forms. Microbiological research of a wound will be held on the 2nd, 8th, 14th, 21nd and 30th day after operation (in study groups before and after the usage of CAP, in control groups once).

    Time frame: 2, 8, 14, 21, 30 days

07

Study locations

1 of 1 sites recruiting
  • State Scientific Centre of Coloproctology
    Moscow, 123423, Russian Federation
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03907306
Lead sponsor
State Scientific Centre of Coloproctology, Russian Federation
Responsible party
Sponsor
First posted
Apr 8, 2019
Start date
Sep 1, 2018
Primary completion
Dec 31, 2019 (estimated)
Completion
Mar 31, 2021 (estimated)
Last update
Apr 8, 2019

Study contacts

Nikita V. Tuktagulov
Contact
dr.tuktagulov@gmail.com
+7 926 188 31 29

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion